The revenues of Akumentis Healthcare have witnessed moderate growth during the past two financial years, with the company’s operating income increasing from ₹398 crore for FY24 to ₹446 crore for FY26.

As per the standalone annual financials provided by the Registrar of Companies, the revenue from operations of the company increased to ₹446 crore for FY26 from ₹434 crore for FY25. During this entire period, the company remained profitable and managed to record moderate growth in its net profits.

Core business operations and notable expenses

Apart from the revenue from its core operations, the company has reported other income of ₹17.3 crore, mostly from interest on bank deposits. The non-operating income boosted the total income of Akumentis Healthcare to ₹464 crore during FY26, compared to ₹449 crore in FY25. The progressive growth in total income reflects consistent cash inflows and retention of commercial emphasis on core pharmaceutical sales.

Though providing services related to various medical disciplines, sales of pharmaceuticals continued to be the only source of operating revenue for the organization. The distribution and market presence of these 167 branded products in major therapeutic fields contributed to the commercial operations and the total revenue recorded in FY26.

On the revenue side, Akumentis Healthcare also managed to improve its aggregate operational expenditure to an extent in the year. Total expenditure declined to ₹360 crore in FY26 from ₹362 crore in FY25. The most significant expense category for the company was employee benefit cost, which stood at ₹130 crore in FY26.

Some other important expenses for the firm were material consumed, which amounted to ₹115 crore during FY26. The expenses incurred on advertising were ₹37 crore, and the travelling expenses were ₹28 crore. 

The total expenditure included legal and professional fees of ₹23 crore. The reduction in employee benefit expenditures helped hold total expenditures lower than those of the prior fiscal year.

Profitability metrics and recent income tax developments

The company reported its net profit at ₹77 crore for FY26, compared to ₹66 crore in FY25. For the purpose of calculating this net profit, an exceptional loss of ₹63 crore in respect of impairment of loans has been made out of this figure to show the underlying financial performance of the business. In FY26, its Return on Capital Employed was at 39.21% and EBITDA margin at 20.14%.

The operating efficiency as measured on a unit basis indicates that Akumentis Healthcare earned Re 0.81 per rupee of operating revenue in FY26. The enterprise recorded current assets of ₹271 crore, including cash and bank balances of ₹199 crore, as its liquidity reserves increased over the financial period under review until March 2026.

For external investment, Akumentis Healthcare had raised a total of $19 million of funding to date. Peak XV Partners is the leading outside investor in the business. The regulatory scene also witnessed positive developments, as parent company AKUM Drugs and its subsidiary, Akumentis Healthcare, were issued an income tax demand notice for ₹134 crore. This notice is a recent legal and financial notification to the group.

Conclusion

The additional non-operating income of ₹17.3 crore helped Akumentis Healthcare report FY26 revenue from operations of ₹446 crore and net profit of ₹77 crore. The company maintained a total expenditure of ₹360 crore, where employee benefits became the primary cost centre of that group with ₹130 crore.

The company’s current asset position stood at ₹271 crore, comprising cash and bank holdings of ₹199 crore, reflecting its robust operational metrics, such as its Return on Capital Employed of 39.21% and its EBITDA margin of 20.14% after accounting for a recent income tax demand notice of ₹134 crore, which the firm is handling in conjunction with AKUM Drugs.